Vitaflo signs new in-licensing agreement for Nordic countries

24-Oct-2007

Navamedic's fully owned subsidiary Vitaflo Scandinavia AB has signed a new in-licensing agreement with OrphaSwiss GmbH for marketing of two products in Sweden, Denmark, Norway and Finland. The products fall within the knowledge areas pain and alcohol/heroin abusement, respectively. Vitaflo already represents OrphaSwiss in the knowledge area alcohol/heroin abusement with the product Naltrexone Vitaflo. Naltrexone Vitaflo is the market leader in its segment in Sweden.

"We are very pleased to see that our new subsidiary continues its strong record of signing new in-licensing agreements and expanding its portfolio. It is particularly encouraging to see that OrphaSwiss, who is already Vitaflo's partner on Naltrexone, demonstrates continued trust in Vitaflo as it's distributor in the Nordic countries", says CEO in Navamedic Øyvind W. Brekke.

Other news from the department business & finance

Most read news

More news from our other portals

Fighting cancer: latest developments and advances